Kiniksa Pharmaceuticals International, plc Investor Event Transcript, Nov 16, 2026
Kiniksa Pharmaceuticals International, plc (KNSA)
Kiniksa Pharmaceuticals International, plc expects a KPL387 Phase three readout in the second half of 2027 and guides 2026 revenue to 1.045 to $1.050 billion. AI summary
Conference Transcript - KNSA 2026-11-16
Roger Song, Conference Host
Hi. Welcome, everyone, to the 2026 Jefferies Global Healthcare Conference in London. My name is Roger Song, senior, and this covers Smica Biotech in the US. It is my pleasure to have a five-side chat with our next company, Conexa, and we have a full crew here. We have Sanchi Patel, CEO, and Rossmo, president and COO, and John Panini, CMO. Welcome, gentlemen. Thank you. Excellent. Before we dive in, a lot of different topics, it is a very good momentum for entire Conexa. Maybe, Sanj, can you give us a state of art about Conexa and why you are excited about the future, particularly for 2027?
Sanj Patel, CEO
Yeah, thank you, Roger, and thanks to Jeffries also for hosting us today. Before I get started, please note we will be making forward-looking statements today that are subject to risks and uncertainties. A review of those statements, risk factors can be found in our SEC filings. So, Roger, yes, a lot to be excited about, actually, at Conixa Pharmaceuticals right now. We're obviously a very growth-orientated company. We've got our lead commercial product, Arcalysis, now, which is about five-plus years on the market since launch, and that's doing incredibly well, But still an awful lot more growth we feel that we can have with ArcList, and really leading and expanding our leadership position in the IL-1 alpha and beta inhibition franchise. So that's what we're very excited about. So beyond ArcList, we've got a thriving pipeline, actually now in our phase three pivotal study with KPL387, which is a monthly IL-1 alpha and beta inhibitor. We'll have readout from our phase three study in the second half of next year. So that's really very exciting. And that's actually a monthly liquid formulation with the potential for an auto-injector. Arculus is a weekly injection. And then beyond that, we have KPL1161, which is a potentially quarterly I1-alpha and beta inhibition molecule. So a lot to be excited about. We'll actually be in the clinic with KPL1161 later this year. So obviously, commercially, we're very much focused on continuing that growth within Arculus, But also excited about bringing KPL 387 and KPL 1161 closer to the market. So a lot to do.
Roger Song, Conference Host
Excellent. Thanks, Sanji. So you do have a very successful commercial franchise, Oculus. Maybe we'll start with that. So we saw the 3Q earning you just reported. It is a pretty good Q on Q growth and then also penetration and continue to grow. Can you just give us the breakdown? What drove that, you know, in terms of, you know, new patient or the longer duration, compliance, and maybe some pricing difference, you know, growth to net. So can you give us some breakdown, the driver for the growth?
Sanj Patel, CEO
Yeah, great. I mean, maybe I'll give you an overview, and then Ross can jump in with some specific numbers. But essentially, most of the growth has been around new patient enrollments on the commercial side. Certainly, duration continues. As I think the last reporter said, it's around three years on therapy. So very much a chronic disorder, if you like, and chronic treatment. But it's been around patient enrollments. You know, you've mentioned compliance that continues to be strong. And pay approval is very strong. And those continue to build. Obviously, it's not easy. So as with any rare disease, it's all about execution and continuing to educate physicians, get our data out there. We obviously had a very successful pivotal study with Rhapsody for Arclist. And so that was very important. On top of that, our registry data continues to support long term treatment. And we're really focused on now increasing the number of multiple prescribers, new prescribers. And I think Ross will talk about how we've done that over the recent months and years. Yeah.
Ross Moat, COO
Yeah. Thank you, Sanj and Roger. So, yeah, certainly all the things that you mentioned, Sanj, and, you know, we see that the commercial fundamentals continue to be very strong, whether that's compliance rate, patient acceptability of therapy, satisfaction on therapy, the payer approval rates all remain very strong across the board for ArcList, but particularly with the new patient enrollments. And ultimately, what's driving that is, you know, satisfaction with treatment when physicians know how to prescribe the drug and continue to prescribe the drug for their next patients. It really has that halo effect. And ultimately, we've seen a substantial increase in the number of physicians that are prescribing archaeologists for recurrent pericarditis. If you look at the breadth of prescribing, we grew in the last quarter by around 450 physicians, new physicians that have not prescribed archaeologists launched to date, who now are, or repeat prescribers. We've got about 30% of our total prescribing pool that have now prescribed for two or more patients. So that grew pretty substantially in the last quarter. But ultimately, our focus is really on the long term and the opportunity that we have ahead with recurrent pericarditis and with Archelis supporting these patients. And if you look at the number of physicians that are looking after these patients to think about the opportunity ahead, we've got around 5,450 unique prescribers who have prescribed Archelis launch to date. But that's out of a total pool of between 25,000 and 30,000 physicians who see a recurrent pericarditis patient in any given year. So clearly, the opportunity for us to keep going on from here for the months, years, quarters, years ahead is pretty substantial. And when you, that's for the breadth and the depth, if you think that we've got around 30% of our prescribing base that are prescribed for two or more patients, again, clearly that's showing that there's very substantial opportunity for us to continue to work on in the years ahead to make sure that we address more and more patients that are suffering from ultimately what is a very debilitating disease, and ArcList is the only approved therapy for recurrent pericarditis.
Roger Song, Conference Host
Excellent. And then since the growth is mostly driven by the new patient, do you know the breakdown between the new patient versus the continuous repeat patient at this moment in your business?
Ross Moat, COO
Yeah, so it's a pretty healthy split, almost a 50-50 split. It's just over 50% of all new enrollments coming in in a given quarter from repeat prescribers. And obviously the other portion being new prescribers. And going off the figures that I just shared around the totality of how many physicians are out there looking after these patients, clearly there's substantial opportunity. But the fact that just over 50% are coming from repeat prescribers, I think, tells you that both the whole strategy around the depth and the breadth of potential prescribing is a huge opportunity for us.
Roger Song, Conference Host
Got it. So 50% of the new prescribers. And then how about new patients, you know, in terms of your business?
Ross Moat, COO
Yeah, so just over 50% of new patients coming in are from repeat prescribers. And what we've seen in aggregate, as Sanj has kind of alluded to a bit on the duration of therapy, that the average duration of therapy is around three years now aggregated up. So that includes patients that have started therapy, stopped and gone back onto therapy. So it's kind of the totality, a moment in time of how many patients there are. But the average ultimately is around three years. And when you look at our penetration into that patient population, if you look at the patients that have suffered for two or more recurrences of the disease, we're currently at the end of Q3, we're around 23% penetrated into the 14,000 patient population that has two or more recurrences. But that is a subsection of the totality of the patients, which is actually around 40,000 patients in total. So that additional 26,000 patients taken up from the 14 to the 40,000 patients are those that are on their first recurrence of the disease within the labeled indication. And we haven't shared a penetration rate within that. But again, the fact we're only 23% of the two plus recurrence group, and there's a larger group of patients on the first recurrence as well, again, all speaks to the opportunity ahead. And when you're thinking about kind of restarts or repeat patients coming off Arclist and back onto Arclist, generally what we see is that when patients stop Arclist, thinking that they may be through the disease, if there is still underlying persistent auto-inflammation ongoing for these patients, generally symptomology will start to build back within these patients within the weeks after the cessation of Arclist. And if patients experience that, they can easily go back onto therapy, as we saw in the clinical trials and we've seen in the real world setting, to continue through what they believe and between them and the patients and the healthcare professionals believe is the total duration of the disease. And around 45% of patients that stop Arculus end up going back onto therapy for a longer treatment period before then they try another stop, hoping that they're through the disease.
Roger Song, Conference Host
Got it. Okay, great. And then, so, you got the ACC guideline to recommend ALKALIST before the steroid. It's probably the second-line option. So, that probably is one of the also driver of the new patients. And the other side is, any other guideline or potential, those kind of evidence can support ALKALIST further into the early line across the practice?
Sanj Patel, CEO
Yeah, maybe, John, you can talk about the registry and other data.
John Paolini, Other
Yeah, absolutely. So the Resonance Registry, which is now the largest registry of recurrent pericarditis in the U.S., over 500 patients. So we have a lot of data that have come from that registry, and we've broken that down in recent presentations at the European Society of Cardiology As well as at the American College of Cardiology, looking at not only third-line, but also second-line use, but even first-line use of ArcList. And so what it shows is that in patients that are coming from NSAIDs and colchicine, that only about a third of patients can actually stay on NSAIDs and colchicine, and then eventually they fail and need to progress to second-line therapy. And what those two analyses showed was, you know, a 96% to 98% reduction in risk of recurrence in those patients who started IL-1 pathway inhibition with Rolanosept versus those patients who transitioned to steroids actually show an increase in the recurrence rate. And so, actually, it's the first time that we've demonstrated superiority of ARKELIST over corticosteroids in second-line management of recurring pericarditis. In addition, there's a small group of patients in the registry, but nevertheless, these are patients who started ARCALIST at the time of diagnosis of recurrent pericarditis, so basically, you know, at the time of first recurrence, and even those patients are showing similar reductions in risk of pericarditis recurrence. So, regardless of line of therapy, what we're seeing is a consistent data set.
Roger Song, Conference Host
Excellent. Okay, I think, Ross, you mentioned the first recurrence and then second plus recurrence. That's one of the distinguish between the patient segments. So the three years average duration on treatment, that's for the multiple recurrence patient. How about the first recurrence patient? Do you see a similar level of the duration on treatment?
Ross Moat, COO
Yeah, so we haven't kind of like segmented that data and shared like via recurrence number. And the reason for that is often that it's actually difficult to know how many recurrences a patient has actually suffered from when they enter onto treatment with ArcList, because a lot of it is self-reported or the patient will say a particular number, a healthcare professional will think of a different number. And every patient feels flares or the symptomology of recurrent pericarditis different. Some of it's more persistent rather than flaring and waxing and waning. So it's difficult to know exactly. So because of that, we just provide externally at least the aggregate duration of therapy. So the approximately three years of duration of Arculus therapy since our launch five and a half years ago is for all of the patients' profiles that are on therapy. And maybe just to put that into context, we know that this is a multi-year chronic disease that these patients have suffered from. And the whole way of treating this disease has ultimately shifted over time from kind of acute treatment during a flare to try to bring down the pain and normalize the patient and then treat again on the next flare and the next flare, more to chronic therapy, acknowledging the type of disease that this is, and that Arculus is ultimately designed for chronic use in these patients. So, because of that, the average treatment duration has been around three years. If you put that against the backdrop of the natural history of the disease, the median is around three years of patients that have two or more recurrences. And we say the median because the largest data set that tracks the natural history of recurrent pericarditis actually finishes at eight years, when about a quarter of the patients were still suffering from the disease at the eight-year time period. So we don't truly know today what the average duration of the disease is for those patients, but suffice to say that it's likely longer than the three years median, given that 25% of the patients are still suffering at five years. So, you know, the current treatment for Oculus right now is around three years. We think it should be used for chronic use throughout the duration of the disease. We've talked a little bit about the restart rates and people trial a stop and need to go back onto therapy. That's very easy to do. And then we'll see how the data evolves ultimately over time.
Roger Song, Conference Host
Awesome. A couple quick number question, right? I think you guided a 2026 revenue, nicely passing a billion dollar, and then imply the fourth quarter growth. So this growth, how much you consider this fourth quarter seasonality versus underlying demand? And then how confident you are, given we already have halfway through the fourth quarter?
Sanj Patel, CEO
Yeah, maybe just to remind the audience what we've guided to now is 1.045 to $1.050 billion for the full year. Obviously, we've talked about the new patient enrollments and our penetration into the market, and that continues to grow. We haven't really talked so much about we don't guide to Q4. Clearly, as Ross said, 23% penetration tells you that there is a lot more opportunity ahead of us. And so we'll just carry on executing, doing all the things that we're doing. We have talked about recently leaning in a lot more on digital marketing and using AI. We've actually got a nice direct-to-consumer campaign that we use, mostly built during AI. Extremely cost-effective, efficient, targeted approach at reaching more and more patients. So we're leveraging those kind of innovative ideas. Obviously, our field force is incredibly effective. The medical affairs team working with all the physicians, educating them on the ACC guidelines is all part of it. So I think ultimately, yes, quarters are important, but we see an awful lot of opportunity in the coming months and years and really building that franchise, of course, with ArcList, but also potentially soon with KPL3 at 701-161.
Roger Song, Conference Host
Yeah, we'll talk about the 387 in a moment. So in terms of the guidance, and then would you be able to give us the 2027 guidance in early year, next year, and then also pre-report the 4Q? I don't remember you did that last year, but certainly the guidance for the new year.
Sanj Patel, CEO
Yeah, we haven't disclosed any future guidance at this point. We'll obviously evaluate it very carefully. We're incredibly data-driven, as you know. We like to execute incredibly well, but it's never easy, so we'll just keep doing what we're doing.
Roger Song, Conference Host
Awesome. And then for the GNA, you seem to have a step up in the 3Q, and then should we think about the 4Q, the guidance, and then should we think about this is going to be a new runway for 2027?
Sanj Patel, CEO
Yeah, again, we haven't guided to the SG&A, but you mentioned a slight step up. I mean, obviously, we are now manufacturing a lot more drug, so that can obviously increase that as well, and we are now moving into late-stage clinical trials. We're in the pivotal trial for 387, which, again, can increase costs, and moving into the clinic with 1161. So that's where some of those costs come from, but still a profitable company, you know, great cash position, and we'll continue to keep going.
Roger Song, Conference Host
Awesome. All right. Let's talk about the KPL387. So you are running phase three right now. I think we already see the top line from the phase two dose ranging. So any additional data from the phase two you will disclose before we see the phase three data?
John Paolini, Other
Yeah, so to remind everybody that the data that we showed, so we did an interval analysis of the phase two study, which was a dose-focusing study looking at four different dose levels of KPL-387, you know, over, you know, over chronic use. And what those data showed were that the 300 milligram sub-Q every four-week dose level provided in terms of cadence and magnitude as well as duration of activity, a profile that's consistent with monthly dosing. So, rapid onset of action, you know, with a time of onset, so, you know, treatment response, you know, in, you know, four days, and also a reduction in normal or normalization of C-reactive protein, you know, again, in about a week. And so that's, you know, consistent with what we've seen with, you know, other IL-1 pathway inhibition, specifically with Rolanosept. And then in terms of durability, what we showed was that, you know, again, consistent suppression of the inflammatory response, you know, throughout the monthly dosing interval. And so that was the information that supported the selection of the 300 milligram monthly dose level, you know, for the phase three trial Pastoral, which is, as Santa mentioned, is ongoing. And so that really is a sufficient data set from phase two at this point. And we haven't discussed or disclosed any further disclosures of data from the phase two program because we're keenly focused on enrolling and dosing in the phase three program. And as Sandra mentioned, with data in the second half of 2027.
Roger Song, Conference Host
Excellent. You know, Arclist basically set a very high bar for everybody, for yourself, for your competitors. And then now you have the monthly version and obviously have other benefit, liquid formulation, et cetera. So how do you think about this profile into the efficacy and safety? What kind of scenario will make those two drugs coexist, having different use cases?
Sanj Patel, CEO
Yeah, I mean, maybe, Ross, you can talk about some of the market research, but obviously, our assumption is a highly efficacious and safe drug. And certainly, the phase two data that John just reviewed gives us a lot of confidence, but we obviously have to continue to execute on the phase three study and then review that data in the second half of next year. But maybe, Ross, talk about the market research.
Ross Moat, COO
Yeah, I'm happy to. We certainly did some market research with different target product profiles, and for KPL387 being a highly efficacious target profile with a monthly liquid formulation sub-Q injection with the potential of being in an auto-injector. And ultimately, we're very encouraged by the feedback that we had from both the patient community and the physician community on that target profile versus either what's currently available commercially or what else is in the clinical trial setting at this point. So what we learned was that for patients, more than 75% of those patients would pick the KPL387 target product profile for treating recurrent pericarditis. More than 92% of healthcare professionals said that's the one that they would also choose for treating their recurrent pericarditis patients, as well as having good feedback around the amount of time that a patient is willing to stay on therapy and how many patients will potentially start therapy. All being advantageous towards the profile of KPL387. So clearly, we think the target product profile could add, you know, very important treatment dynamic and treatment options for future recurrent pericarditis patients. But clearly, we are very focused on the clinical trial execution and operations. And we continue to be focused on both our list and our pipeline.
Roger Song, Conference Host
Excellent. And then I don't believe you disclosed exactly what the target product profile. So should we assume comparable efficacy safety? I think, Sanji, you mentioned, you know, highly efficacious and safe product.
Sanj Patel, CEO
Yeah, I mean, that's exactly what it will be. So obviously, we'll have to see what the data is, data are, but highly efficacious and safe is very important to us. You know, whether it has to be better or slightly worse, I'm not quite sure. Ross has reviewed the market research, but we'll see what the data are.
Roger Song, Conference Host
Okay. All right. And then in terms of the pricing, because this is monthly, right? And then on the other side is you do have some compliance dynamic over there. So how should you think about the pricing between the 387 versus Oculus?
Sanj Patel, CEO
Yeah, it's a bit too early to talk about pricing at this point. Clearly, though, Roger, as you can know, we know how to price drugs, and we've done that a number of times, both here and previously. But obviously, again, value dependent, data dependent. And once we get the data, once we get approval, we will share the price.
Roger Song, Conference Host
You do have a partnership with Regeneron. So what's the dynamic over there? So between the new monthly versus the weekly alkalis?
Sanj Patel, CEO
Well, 387 is a wholly owned, you know, self-generated by Kinexa. It's not part of the Regeneron profit split. We do not have a non-compete with Regeneron for developing 387. So we'll carry on. We have a great partnership with Regeneron. And I think obviously it's very important to have additional treatment options for patients. And that's what we're tending to do.
Roger Song, Conference Host
Do they have like a first right to referral or, you know, first right to the right to first negotiations? We haven't discussed that. Got it. Awesome. You know, RP is a rare disease, but seems Oculus is the, you know, very dominant player over there. A couple other mechanism is trying to do something over there. So how do you think about those mechanisms, particularly they may generate some data next year?
John Paolini, Other
Sure. So what we know, it's important to go back to the fundamentals of the disease biology and then understand how a targeted strategy works in that particular disease biology. And what we know from the data is that recurrent pericarditis is a disease that's driven primarily by interleukin-1, and specifically both interleukin-1-alpha and interleukin-1-beta. Interleukin-1-alpha is important in a localized tissue response after pericardial injury, and then that sets off the activation of the inflammasome cascade amplification and then production of interleukin-1-beta, which recruits the systemic inflammatory response. And so it's very important to block both of those cytokines in order to gain control of the disease. And that's what we learned from the Arculus program, and that's why when we were presented with the option of how do we, you know, do more for patients, and how do we create additional treatment options, we went to double down, if you will, on that mechanism in blocking interleukin-1-alpha and beta. And so, therefore, that is the genesis, if you will, of KPL-387. And so, you know, that's really where our focus is, and that's, and as we know, the Arculus program set a very high bar for efficacy In terms of onset of action and durability. And so, you know, that's how the KPL 387 program with Pastoral has been designed in order to, you know, reinforce that finding. And so from there, you know, what we hope to provide for patients and physicians is the best treatment options going forward.
Sanj Patel, CEO
I think what John's saying is that we've got the right mechanism, the right focus, hitting both I1-alpha, inhibiting both alpha and beta. And there are other mechanisms out there. Some of them mostly focus downstream on the beta and the inflammasome. That's not what we're doing.
Roger Song, Conference Host
Okay, awesome. Just lastly, in terms of the capital allocation, you do have a lot of cash and it's a profitable business. And then you also say you have extremely high bar for BD, and then no share backpack. So how should we think about the capital allocation among your commercial pipeline and etc?
Sanj Patel, CEO
Yeah, I mean, we live and breathe capital allocation, which we do every day. And we've done that for many years. I think bottom line is we are very much focused on creating value. And, you know, we've got a high bar, we've got a great pipeline, a great commercial products, we expect to have more obviously programs that are approved in the future. And we'll be very careful. That said, we'll always look at opportunities. But because what we have, we don't have to necessarily do anything, which is the best type of situation to be in, particularly when you're considering additional value creating opportunities. So we'll continue to be very judicious, very focused on capital allocation, and just building the growth around this both commercial and clinical pipeline.
Roger Song, Conference Host
Excellent. Thank you, everyone. Thank you, Tim. Thank you.